According to recent studies and RCTs in various countries, the antiparasitic drug ivermectin – a WHO essential medicine – is achieving a covid-19 risk reduction of up to 98% in pre-exposure prophylaxis and up to 91% in early treatment. A recent French study found a reduction in severe and fatal covid by 100% even in high-risk nursing home patients with an average age of 90.
Moreover, an analysis just published in the International Journal of Antimicrobial Agents found that African countries using ivermectin as prophylaxis against parasites report a much lower – in fact, near zero – covid incidence compared to other African and non-African countries.
The very high reported effectiveness of low-cost ivermectin against SARS-like coronavirus infections may turn out to be a major medical discovery. Doctors and health authorities are encouraged to consider the ivermectin studies overview and the ivermectin-based US-FLCCC treatment protocol.
See also: On the treatment of covid-19.
Note: Patients are asked to consult a doctor.